# GT Biopharma

Source: https://onco.cc/companies/gt-biopharma/  
OnCo record `gt-biopharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

GT Biopharma is a San Francisco company making proteins that switch on a patient's own natural killer cells, a kind of immune cell, and point them at cancer. Its two lead medicines are in early trials in leukaemia and in solid tumours.

## Summary

GT Biopharma, Inc., of San Francisco, develops Tri-specific Killer Engager (TriKE) fusion proteins, licensed from work led by Jeffrey Miller at the Masonic Cancer Center of the University of Minnesota. Each binds CD16 on natural killer cells, a tumour antigen, and carries IL-15 to drive natural killer cell expansion; the company states its second-generation camelid nanobody TriKEs are 10 to 40 times more potent than the first. On its pipeline page, GTB-3650 (CD33) is in a phase 1 dose-escalation trial in relapsed or refractory CD33-expressing leukaemias and high-risk myelodysplastic syndrome (NCT06594445), and GTB-5550 (B7-H3), given under the skin, dosed its first patient in a phase 1 basket trial in solid tumours in May 2026 (NCT07541573).

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: GT Biopharma, Inc.
- HQ: San Francisco, CA
- Type: biotech
- Website: https://www.gtbiopharma.com/
- Ticker: GTBP

## Notes

- The October 2026 S-1 describes the TriKE platform and the University of Minnesota trial agreements but names no candidate; candidates, phases and trial numbers were read on the company's pipeline page on 4 November 2026. Neither trial has an OnCo record.

## Sources

- SEC: GT Biopharma Form S-1, October 2026: https://www.sec.gov/Archives/edgar/data/109657/000149315226046618/forms-1.htm
- GT Biopharma: product pipeline: https://www.gtbiopharma.com/product-pipeline/overview
- Official website: https://www.gtbiopharma.com/

## Connected records

- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [NK cell engagers](https://onco.cc/technologies/nk-cell-engagers/)
- targets: [B7-H3](https://onco.cc/targets/b7h3/), [CD33](https://onco.cc/targets/cd33/)
- drugs: [GTB-3650](https://onco.cc/drugs/gtb-3650/), [GTB-5550](https://onco.cc/drugs/gtb-5550/)

---
JSON: https://onco.cc/api/v1/entities/gt-biopharma.json